Your browser doesn't support javascript.
loading
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson, Kenneth C; Auclair, Daniel; Adam, Stacey J; Agarwal, Amit; Anderson, Melissa; Avet-Loiseau, Hervé; Bustoros, Mark; Chapman, Jessica; Connors, Dana E; Dash, Ajeeta; Di Bacco, Alessandra; Du, Ling; Facon, Thierry; Flores-Montero, Juan; Gay, Francesca; Ghobrial, Irene M; Gormley, Nicole J; Gupta, Ira; Higley, Howard; Hillengass, Jens; Kanapuru, Bindu; Kazandjian, Dickran; Kelloff, Gary J; Kirsch, Ilan R; Kremer, Brandon; Landgren, Ola; Lightbody, Elizabeth; Lomas, Oliver C; Lonial, Sagar; Mateos, María-Victoria; Montes de Oca, Rocio; Mukundan, Lata; Munshi, Nikhil C; O'Donnell, Elizabeth K; Orfao, Alberto; Paiva, Bruno; Patel, Reshma; Pugh, Trevor J; Ramasamy, Karthik; Ray, Jill; Roshal, Mikhail; Ross, Jeremy A; Sigman, Caroline C; Thoren, Katie L; Trudel, Suzanne; Ulaner, Gary; Valente, Nancy; Weiss, Brendan M; Zamagni, Elena; Kumar, Shaji K.
Affiliation
  • Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut.
  • Adam SJ; Foundation for the National Institutes of Health, North Bethesda, Maryland.
  • Agarwal A; US Medical Oncology, Bristol-Myers Squibb, Summit, New Jersey.
  • Anderson M; Takeda Pharmaceuticals, Cambridge, Massachusetts.
  • Avet-Loiseau H; Laboratoire d'Hématologie, Pôle Biologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Bustoros M; Division of Hematology and Medical Oncology, Cornell University/New York Presbyterian Hospital, New York, New York.
  • Chapman J; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Connors DE; Foundation for the National Institutes of Health, North Bethesda, Maryland.
  • Dash A; Takeda Pharmaceuticals, Cambridge, Massachusetts.
  • Di Bacco A; Takeda Pharmaceuticals, Cambridge, Massachusetts.
  • Du L; GlaxoSmithKline, Collegeville, Pennsylvania.
  • Facon T; Department of Hematology, Lille University Hospital, Lille, France.
  • Flores-Montero J; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain.
  • Gay F; Myeloma Unit, Division of Hematology, Azienda Ospedaliero Università Città della Salute e della Scienza, Torino, Italy.
  • Ghobrial IM; Preventative Cancer Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Gormley NJ; Division of Hematologic Malignancies 2, Office of Oncologic Disease, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.
  • Gupta I; GlaxoSmithKline, Collegeville, Pennsylvania.
  • Higley H; CCS Associates, Inc., San Jose, California.
  • Hillengass J; Division of Hematology and Oncology, Roswell Park Cancer Institute, Buffalo, New York.
  • Kanapuru B; Division of Hematologic Malignancies 2, Office of Oncologic Disease, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland.
  • Kazandjian D; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Kelloff GJ; Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland.
  • Kirsch IR; Translational Medicine, Adaptive Biotechnologies, Seattle, Washington.
  • Kremer B; GlaxoSmithKline, Collegeville, Pennsylvania.
  • Landgren O; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Lightbody E; Preventative Cancer Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Lomas OC; Preventative Cancer Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Lonial S; Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, Georgia.
  • Mateos MV; Haematology Department, University of Salamanca, Salamanca, Spain.
  • Montes de Oca R; GlaxoSmithKline, Collegeville, Pennsylvania.
  • Mukundan L; CCS Associates, Inc., San Jose, California.
  • Munshi NC; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • O'Donnell EK; Multiple Myeloma Disease Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Orfao A; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain.
  • Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain.
  • Patel R; Janssen Research & Development, Spring House, Pennsylvania.
  • Pugh TJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Ramasamy K; Cancer and Haematology Centre, Oxford University Hospitals, Oxford, United Kingdom.
  • Ray J; BioOncology, Genentech Inc., South San Francisco, California.
  • Roshal M; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ross JA; Precision Medicine, Oncology, AbbVie, Inc., North Chicago, Illinois.
  • Sigman CC; CCS Associates, Inc., San Jose, California.
  • Thoren KL; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Trudel S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Ulaner G; Hoag Cancer Center, Irvine, California.
  • Valente N; BioOncology, Genentech Inc., South San Francisco, California.
  • Weiss BM; Janssen Research & Development, Spring House, Pennsylvania.
  • Zamagni E; Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Kumar SK; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Clin Cancer Res ; 27(19): 5195-5212, 2021 10 01.
Article de En | MEDLINE | ID: mdl-34321279
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Myélome multiple Type d'étude: Diagnostic_studies / Observational_studies Limites: Humans Langue: En Journal: Clin Cancer Res Sujet du journal: NEOPLASIAS Année: 2021 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Myélome multiple Type d'étude: Diagnostic_studies / Observational_studies Limites: Humans Langue: En Journal: Clin Cancer Res Sujet du journal: NEOPLASIAS Année: 2021 Type de document: Article